Seward B Rutkove1, Kush Kapur2, Craig M Zaidman3, Jim S Wu4, Amy Pasternak5, Lavanya Madabusi2, Sung Yim1, Adam Pacheck1, Heather Szelag2, Tim Harrington2, Basil T Darras2. 1. Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. 2. Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA. 3. Department of Neurology, Washington University in St Louis, St Louis, MO. 4. Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. 5. Department of Physical Therapy Services and Occupational Therapy Services, Boston Children's Hospital, Boston, MA.
Abstract
OBJECTIVE: Sensitive, objective, and easily applied methods for evaluating disease progression and response to therapy are needed for clinical trials in Duchenne muscular dystrophy (DMD). In this study, we evaluated whether electrical impedance myography (EIM) could serve this purpose. METHODS: In this nonblinded study, 36 boys with DMD and 29 age-similar healthy boys underwent multifrequency EIM measurements for up to 2 years on 6 muscles unilaterally along with functional assessments. A linear mixed-effects model with random intercept and slope terms was used for the analysis of multifrequency EIM values and functional measures. Seven DMD boys were initiated on corticosteroids; these data were analyzed using a piecewise linear mixed-effects model. RESULTS: In boys > 7.0 years old, a significant difference in the slope of EIM phase ratio trajectories in the upper extremity was observed by 6 months of -0.074/month, p = 0.023, 95% confidence interval (CI) = -0.013, -0.14; at 2 years, this difference was -0.048/month, p < 0.0001, 95% CI = -0.028, -0.068. In boys ≤ 7.0 years old, differences appeared at 6 months in gastrocnemius (EIM phase slope = -0.83 °/kHz/mo, p = 0.007, 95% CI = -0.26, -1.40). EIM outcomes showed significant differences earlier than functional tests. Initiation of corticosteroids significantly improved the slope of EIM phase ratio (0.057/mo, p = 0.00019, 95% CI = 0.028, 0.086) and EIM phase slope (0.14 °/kHz/mo, p = 0.013, 95% CI = 0.028, 0.25), consistent with corticosteroids' known clinical benefit. INTERPRETATION: EIM detects deterioration in muscles of both younger and older boys by 6 months; it also identifies the therapeutic effect of corticosteroid initiation. Because EIM is rapid to apply, painless, and requires minimal operator training, the technique deserves to be further evaluated as a biomarker in DMD clinical therapeutic trials. Ann Neurol 2017;81:622-632.
OBJECTIVE: Sensitive, objective, and easily applied methods for evaluating disease progression and response to therapy are needed for clinical trials in Duchenne muscular dystrophy (DMD). In this study, we evaluated whether electrical impedance myography (EIM) could serve this purpose. METHODS: In this nonblinded study, 36 boys with DMD and 29 age-similar healthy boys underwent multifrequency EIM measurements for up to 2 years on 6 muscles unilaterally along with functional assessments. A linear mixed-effects model with random intercept and slope terms was used for the analysis of multifrequency EIM values and functional measures. Seven DMDboys were initiated on corticosteroids; these data were analyzed using a piecewise linear mixed-effects model. RESULTS: In boys > 7.0 years old, a significant difference in the slope of EIM phase ratio trajectories in the upper extremity was observed by 6 months of -0.074/month, p = 0.023, 95% confidence interval (CI) = -0.013, -0.14; at 2 years, this difference was -0.048/month, p < 0.0001, 95% CI = -0.028, -0.068. In boys ≤ 7.0 years old, differences appeared at 6 months in gastrocnemius (EIM phase slope = -0.83 °/kHz/mo, p = 0.007, 95% CI = -0.26, -1.40). EIM outcomes showed significant differences earlier than functional tests. Initiation of corticosteroids significantly improved the slope of EIM phase ratio (0.057/mo, p = 0.00019, 95% CI = 0.028, 0.086) and EIM phase slope (0.14 °/kHz/mo, p = 0.013, 95% CI = 0.028, 0.25), consistent with corticosteroids' known clinical benefit. INTERPRETATION: EIM detects deterioration in muscles of both younger and older boys by 6 months; it also identifies the therapeutic effect of corticosteroid initiation. Because EIM is rapid to apply, painless, and requires minimal operator training, the technique deserves to be further evaluated as a biomarker in DMD clinical therapeutic trials. Ann Neurol 2017;81:622-632.
Authors: Jia Li; Tom R Geisbush; Glenn D Rosen; Jennifer Lachey; Aaron Mulivor; Seward B Rutkove Journal: Muscle Nerve Date: 2014-06 Impact factor: 3.217
Authors: E Mazzone; G Vasco; M P Sormani; Y Torrente; A Berardinelli; S Messina; A D'Amico; L Doglio; L Politano; F Cavallaro; S Frosini; L Bello; S Bonfiglio; E Zucchini; R De Sanctis; M Scutifero; F Bianco; F Rossi; M C Motta; A Sacco; M A Donati; T Mongini; A Pini; R Battini; E Pegoraro; M Pane; S Gasperini; S Previtali; S Napolitano; D Martinelli; C Bruno; G Vita; G Comi; E Bertini; E Mercuri Journal: Neurology Date: 2011-07-06 Impact factor: 9.910
Authors: Jill E Mayhew; Julaine M Florence; Thomas P Mayhew; Erik K Henricson; Robert T Leshner; Robert J McCarter; Diana M Escolar Journal: Muscle Nerve Date: 2007-01 Impact factor: 3.217
Authors: Jerry R Mendell; Louise R Rodino-Klapac; Zarife Sahenk; Kandice Roush; Loren Bird; Linda P Lowes; Lindsay Alfano; Ann Maria Gomez; Sarah Lewis; Janaiah Kota; Vinod Malik; Kim Shontz; Christopher M Walker; Kevin M Flanigan; Marco Corridore; John R Kean; Hugh D Allen; Chris Shilling; Kathleen R Melia; Peter Sazani; Jay B Saoud; Edward M Kaye Journal: Ann Neurol Date: 2013-09-10 Impact factor: 10.422
Authors: Rebecca J Willcocks; William D Rooney; William T Triplett; Sean C Forbes; Donovan J Lott; Claudia R Senesac; Michael J Daniels; Dah-Jyuu Wang; Ann T Harrington; Gihan I Tennekoon; Barry S Russman; Erika L Finanger; Barry J Byrne; Richard S Finkel; Glenn A Walter; H Lee Sweeney; Krista Vandenborne Journal: Ann Neurol Date: 2016-02-19 Impact factor: 10.422
Authors: Janbernd Kirschner; Joachim Schessl; Ulrike Schara; Bernd Reitter; Georg M Stettner; Elke Hobbiebrunken; Ekkehard Wilichowski; Günther Bernert; Simone Weiss; Florian Stehling; Gert Wiegand; Wolfgang Müller-Felber; Simone Thiele; Ulrike Grieben; Maja von der Hagen; Jürg Lütschg; Claudia Schmoor; Gabriele Ihorst; Rudolf Korinthenberg Journal: Lancet Neurol Date: 2010-08-26 Impact factor: 44.182
Authors: Craig M McDonald; Erik K Henricson; Jay J Han; R Ted Abresch; Alina Nicorici; Gary L Elfring; Leone Atkinson; Allen Reha; Samit Hirawat; Langdon L Miller Journal: Muscle Nerve Date: 2010-04 Impact factor: 3.217
Authors: Bhaskar Roy; Basil T Darras; Craig M Zaidman; Jim S Wu; Kush Kapur; Seward B Rutkove Journal: Clin Neurophysiol Date: 2019-02-12 Impact factor: 3.708
Authors: Marie Mortreux; Janice A Nagy; Haowen Zhong; Dong-Min Sung; Holly A Concepcion; Melanie Leitner; Laura Dalle Pazze; Seward B Rutkove Journal: J Vis Exp Date: 2022-06-08 Impact factor: 1.424
Authors: Karlien Mul; Chad Heatwole; Katy Eichinger; Nuran Dilek; William B Martens; Baziel G M Van Engelen; Rabi Tawil; Jeffrey M Statland Journal: Muscle Nerve Date: 2018-04-17 Impact factor: 3.217
Authors: Samantha LoRusso; Nicholas E Johnson; Michael P McDermott; Katy Eichinger; Russell J Butterfield; Elena Carraro; Kiley Higgs; Leann Lewis; Karlien Mul; Sabrina Sacconi; Valeria A Sansone; Perry Shieh; Baziel van Engelen; Kathryn Wagner; Leo Wang; Jeffrey M Statland; Rabi Tawil Journal: BMC Neurol Date: 2019-09-10 Impact factor: 2.474